SSX2 Human

Synovial Sarcoma, X Breakpoint 2 (SSX2) is a member of the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins are known for their role in transcriptional repression and their involvement in cancer immunotherapy. The recombinant form of SSX2 is produced using various expression systems, such as E. coli or HEK293T cells, to study its function and potential therapeutic applications.

The SSX2 gene is located on the X chromosome at position Xp11.22 . It encodes a protein that consists of 188 amino acids and has a molecular mass of approximately 24 kDa . The recombinant SSX2 protein often includes additional tags, such as a His-tag, to facilitate purification and detection .

SSX2 proteins function as transcriptional repressors, meaning they can inhibit the expression of certain genes . This repression is crucial in regulating various cellular processes. Additionally, SSX2 proteins are capable of eliciting spontaneous humoral and cellular immune responses in cancer patients, making them valuable targets for cancer vaccine-based immunotherapy .

SSX2 is particularly significant in the context of synovial sarcoma, a type of cancer that typically affects young adults. Synovial sarcomas are characterized by a specific chromosomal translocation, t(X;18)(p11.2;q11.2), which results in the fusion of the SSX2 gene on the X chromosome with the SYT gene on chromosome 18 . The resulting fusion protein is believed to contribute to the oncogenic properties of synovial sarcoma cells.

Recombinant SSX2 proteins are used extensively in research to understand their role in cancer and to develop potential therapeutic strategies. These proteins are produced in various expression systems and purified using chromatographic techniques . They are also used to generate antibodies and other reagents for studying SSX2 function and interactions.